From: Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
DLB (n = 72) | AD (n = 38) | Controls (n = 38) | |
---|---|---|---|
Female (n, %) | 7 (10%) | 3 (8%) | 5 (13%) |
Age (mean ± SD) | 68 ± 6 | 68 ± 6 | 67 ± 6 |
MMSE (median [IQR]) | 23 [21–26]b | 22 [18–25]b | 29 [28–30] |
APOEε4 carrier (n, %) | 39 (57%)a | 26 (72%)a | 12 (32%) |
CSF AD biomarkers Innotest (median [IQR]) | |||
Aβ1-42 (pg/ml)* | 790 [638–1040]b,d | 620 [562–660]b | 1123 [1022–1291] |
t-tau (pg/ml) | 306 [228–368]b,d | 611 [498–791]b | 230 [187–271] |
p-tau (pg/ml) | 47 [35–60]d | 79 [65–99]b | 44 [34–50] |
CSF tau/Aβ42 > 0.52 (n, %) | 23 (33%)b,d | 38 (100%)b | 0 (0%) |
CSF Aβ peptides MSD (mean ± SD) | |||
Aβ42 (pg/ml) | 441 ± 185b,d | 304 ± 71b | 692 ± 205 |
Aβ40 (pg/ml) | 5432 ± 1340a | 5897 ± 1066 | 6243 ± 1500 |
Aβ38 (pg/ml) | 2247 ± 638a,c | 2524 ± 547 | 2676 ± 703 |
Aβ42/Aβ40 ratio | 0.08 ± 0.03b,d | 0.05 ± 0.01b | 0.11 ± 0.02 |
Aβ42/Aβ38 ratio | 0.20 ± 0.07b,d | 0.12 ± 0.03b | 0.26 ± 0.04 |
Aβ38/Aβ40 ratio | 0.41 ± 0.03a,c | 0.43 ± 0.04 | 0.43 ± 0.02 |